clonazepam has been researched along with Agoraphobia in 19 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treatment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia." | 9.15 | Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. ( Amrein, R; Crippa, JA; da Costa, RT; de Carvalho, MR; de Cerqueira, AC; de O E Silva, AC; de-Melo-Neto, VL; Dias, GP; Freire, RC; Hallak, JE; King, AL; Levitan, MN; Mezzasalma, MA; Mochcovitch, MD; Nardi, AE; Nascimento, I; Sardinha, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M, 2011) |
| "At the therapeutic endpoint, clonazepam (N = 222) proved clinically and statistically superior to placebo (N = 216) in change in the number of panic attacks and in Clinical Global Impressions-Severity of Illness (CGI-S) and CGI-Change scores, Patient's Global Impression of Change scores, amount of fear and avoidance associated with phobic symptoms, and duration of anticipatory anxiety." | 9.09 | Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. ( Moroz, G; Rosenbaum, JF, 1999) |
| "To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients." | 9.09 | Double-blind clonazepam vs placebo in panic disorder treatment. ( Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM; Zin, W, 2000) |
| "In this multicenter, parallel-group, placebo-controlled, fixed-dose study, the efficacy, safety, dosing characteristics, and discontinuation of clonazepam were analyzed in patients with panic disorder." | 9.08 | Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. ( Bowden, CL; Moroz, G; Rosenbaum, JF, 1997) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 7.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 7.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| "Fifty patients with panic disorder or agoraphobia with panic attacks with treated with clonazepam, a high potency benzodiazepine." | 7.67 | Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. ( Pollack, MH; Rosenbaum, JF; Spier, SA; Tesar, GE, 1986) |
| "The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treatment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia." | 5.15 | Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. ( Amrein, R; Crippa, JA; da Costa, RT; de Carvalho, MR; de Cerqueira, AC; de O E Silva, AC; de-Melo-Neto, VL; Dias, GP; Freire, RC; Hallak, JE; King, AL; Levitan, MN; Mezzasalma, MA; Mochcovitch, MD; Nardi, AE; Nascimento, I; Sardinha, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M, 2011) |
| "In the group that received clonazepam, by the end of the 6th week there was a statistically significant clinical improvement, shown by the remission of panic attacks (p < 0." | 5.10 | Therapeutic response to benzodiazepine in panic disorder subtypes. ( Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM; Versiani, M; Zin, WA, 2003) |
| "At the therapeutic endpoint, clonazepam (N = 222) proved clinically and statistically superior to placebo (N = 216) in change in the number of panic attacks and in Clinical Global Impressions-Severity of Illness (CGI-S) and CGI-Change scores, Patient's Global Impression of Change scores, amount of fear and avoidance associated with phobic symptoms, and duration of anticipatory anxiety." | 5.09 | Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. ( Moroz, G; Rosenbaum, JF, 1999) |
| "To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients." | 5.09 | Double-blind clonazepam vs placebo in panic disorder treatment. ( Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM; Zin, W, 2000) |
| "In this multicenter, parallel-group, placebo-controlled, fixed-dose study, the efficacy, safety, dosing characteristics, and discontinuation of clonazepam were analyzed in patients with panic disorder." | 5.08 | Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. ( Bowden, CL; Moroz, G; Rosenbaum, JF, 1997) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 3.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 3.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| "Ten cases are presented--two in detail--in which clonazepam was used successfully in patients with treatment-resistant panic disorder with or without agoraphobia." | 3.67 | Successful use of clonazepam in patients with treatment-resistant panic disorder. ( Rosenbaum, JF; Tesar, GE, 1986) |
| "Fifty patients with panic disorder or agoraphobia with panic attacks with treated with clonazepam, a high potency benzodiazepine." | 3.67 | Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. ( Pollack, MH; Rosenbaum, JF; Spier, SA; Tesar, GE, 1986) |
| "Clonazepam is a high-potency 1,4-benzodiazepine derivative with an intermediate to long elimination half-life that is used mainly in neurology as an antiepileptic." | 1.27 | Clonazepam in the treatment of patients with recurrent panic attacks. ( Annable, L; Beaudry, P; Chouinard, G; Fontaine, R, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nardi, AE | 4 |
| Valença, AM | 4 |
| Freire, RC | 1 |
| Mochcovitch, MD | 1 |
| Amrein, R | 1 |
| Sardinha, A | 1 |
| Levitan, MN | 1 |
| Nascimento, I | 4 |
| de-Melo-Neto, VL | 1 |
| King, AL | 1 |
| de O E Silva, AC | 1 |
| Veras, AB | 1 |
| Dias, GP | 1 |
| Soares-Filho, GL | 1 |
| da Costa, RT | 1 |
| Mezzasalma, MA | 4 |
| de Carvalho, MR | 1 |
| de Cerqueira, AC | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Versiani, M | 2 |
| Starcevic, V | 1 |
| Kolar, D | 1 |
| Latas, M | 1 |
| Bogojevic, G | 1 |
| Kelin, K | 1 |
| Zin, WA | 2 |
| Lopes, FL | 2 |
| Choi, YH | 1 |
| Vincelli, F | 1 |
| Riva, G | 1 |
| Wiederhold, BK | 1 |
| Lee, JH | 1 |
| Park, KH | 1 |
| Rosenbaum, JF | 8 |
| Moroz, G | 2 |
| Bowden, CL | 1 |
| Zin, W | 1 |
| Ontiveros, A | 1 |
| Fontaine, R | 3 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Lawrence, JM | 1 |
| Davidson, JR | 1 |
| Fava, M | 1 |
| MacLaughlin, RA | 1 |
| Tesar, GE | 5 |
| Pollack, MH | 3 |
| Cohen, LS | 1 |
| Hirsch, M | 1 |
| Herman, JB | 1 |
| Sachs, GS | 1 |
| Spier, SA | 2 |
| Woods, SW | 1 |
| Beaudry, P | 1 |
| Chouinard, G | 1 |
| Annable, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia[NCT02852577] | Phase 4 | 120 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clonazepam and Agoraphobia
| Article | Year |
|---|---|
Continuation treatment of panic disorder with high-potency benzodiazepines.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Benzodiazepines; Clonazepam; Humans; P | 1990 |
8 trials available for clonazepam and Agoraphobia
| Article | Year |
|---|---|
Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine.
Topics: Adolescent; Adult; Agoraphobia; Clonazepam; Female; Humans; Male; Middle Aged; Panic Disorder; Parox | 2011 |
Therapeutic response to benzodiazepine in panic disorder subtypes.
Topics: Adolescent; Adult; Agoraphobia; Clonazepam; Female; GABA Modulators; Humans; Male; Middle Aged; Pani | 2003 |
Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Clonazepam; Cognitive Behavior | 2005 |
Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group.
Topics: Adolescent; Adult; Aged; Agoraphobia; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Met | 1997 |
Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages.
Topics: Adolescent; Adult; Aged; Agoraphobia; Ambulatory Care; Clonazepam; Comorbidity; Double-Blind Method; | 1999 |
Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks.
Topics: Administration, Inhalation; Administration, Oral; Adult; Agoraphobia; Anticonvulsants; Carbon Dioxid | 2000 |
Double-blind clonazepam vs placebo in panic disorder treatment.
Topics: Adult; Agoraphobia; Analysis of Variance; Clonazepam; Double-Blind Method; Female; GABA Modulators; | 2000 |
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Clonazepam; Dehydroepiandrosterone; Double | 1989 |
10 other studies available for clonazepam and Agoraphobia
| Article | Year |
|---|---|
Panic disorder patients at the time of air strikes.
Topics: Adult; Agoraphobia; Aircraft; Alprazolam; Catchment Area, Health; Clonazepam; Female; Follow-Up Stud | 2002 |
Sodium valproate and clonazepam for treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Clonazepam; Drug Synergism; Drug Therapy, Combination; Female; gamma-Aminobutyri | 1992 |
Treatment of panic disorder and benzodiazepine withdrawal with valproate.
Topics: Adult; Agoraphobia; Clonazepam; Diazepam; Dose-Response Relationship, Drug; Humans; Male; Panic Diso | 1991 |
Switching patients from alprazolam to clonazepam.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clonazepam; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Clonazepam in the treatment of panic disorder and agoraphobia.
Topics: Adult; Aged; Agoraphobia; Alprazolam; Carbon Dioxide; Clonazepam; Fear; Female; Humans; Male; Middle | 1987 |
Treatment of panic disorder and agoraphobia with clonazepam.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepino | 1986 |
Successful use of clonazepam in patients with treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clonazepam; D | 1986 |
Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up.
Topics: Adolescent; Adult; Aged; Agoraphobia; Anxiety Disorders; Clonazepam; Fear; Female; Follow-Up Studies | 1986 |
Clonazepam in the treatment of patients with recurrent panic attacks.
Topics: Adult; Agoraphobia; Anxiety Disorders; Benzodiazepinones; Clonazepam; Drug Evaluation; Fear; Female; | 1986 |
Clonazepam for panic disorders and agitation.
Topics: Adult; Agoraphobia; Benzodiazepinones; Clonazepam; Fear; Female; Humans; Male; Panic; Phobic Disorde | 1985 |